Review

Science Review: Vasopressin and the cardiovascular system
part 2 – clinical physiology
Cheryl L Holmes¹, Donald W Landry² and John T Granton³

¹Staff intensivist, Department of Medicine, Division of Critical Care, Kelowna General Hospital, Kelowna BC, Canada
²Associate Professor, Department of Medicine, Columbia University, New York, New York, USA
³Assistant Professor of Medicine, Faculty of Medicine, and Program Director, Critical Care Medicine, University of Toronto, and Consultant in Pulmonary and Critical Care Medicine, Director Pulmonary Hypertension Program, University Health Network, Toronto, Ontario, Canada

Corresponding author: John T Granton, John.Granton@uhn.on.ca

Published online: 26 June 2003
Critical Care 2004, 8:15-23 (DOI 10.1186/cc2338)
This article is online at http://ccforum.com/content/8/1/15
© 2004 BioMed Central Ltd (Print ISSN 1364-8535; Online ISSN 1466-609X)

Abstract
Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-sensitive K⁺ channels, nitric oxide pathways, and interaction with adrenergic agents. We explore the complex and contradictory studies of vasopressin on cardiac inotropy and coronary vascular tone. Finally, we summarize the clinical studies of vasopressin in shock states, which to date have been relatively small and have focused on physiologic outcomes. Because of potential adverse effects of vasopressin, clinical use of vasopressin in vasodilatory shock should await a randomized controlled trial of the effect of vasopressin’s effect on outcomes such as organ failure and mortality.

Keywords adrenergic agents, antidiuretic hormone, cardiac inotropy, hypotension, nitric oxide, oxytocin, physiology, potassium channels, receptors, septic shock, smooth muscle, vascular, vasoconstriction, vasodilation, vasopressin

Introduction
Vasopressin is a hormone that is essential for both osmotic and cardiovascular homeostasis. A deficiency in vasopressin exists in some shock states and replacement of physiologic levels of vasopressin can restore vascular tone. Vasopressin is therefore emerging as a rational therapy for shock. Preliminary studies [1–12] show that infusion of low-dose vasopressin in patients who have vasodilatory shock decreases norepinephrine (noradrenaline) dose requirements, maintains blood pressure and cardiac output, decreases pulmonary vascular resistance, and increases urine output. Thus, low-dose vasopressin could improve renal and other organ function in septic shock. Paradoxically, vasopressin has also been demonstrated to cause vasodilation in some vascular beds, distinguishing this hormone from other vasoconstrictor agents.

The present review explores the vascular actions of vasopressin. In part 1 of the review we discussed the signaling pathways, distribution of vasopressin receptors, and the structural elements responsible for the functional diversity found within the vasopressin receptor family. We now explore the mechanisms of vasoconstriction and vasodilation of the vascular smooth muscle, with an emphasis on vasopressin interaction in these pathways. We discuss the seemingly contradictory studies and some new information regarding the actions of vasopressin on the heart. Finally, we summarize the clinical trials of vasopressin in vasodilatory shock states and comment on areas for future research.

Vascular smooth muscle contraction pathways and vasopressin interaction
Vasopressin restores vascular tone in vasoplegic (catecholamine-resistant) shock states by at least four known mechanisms [13]: through activation of V₁ vascular receptors (V₁R); modulation of ATP-sensitive K⁺ channels (KᵦΤP); modulation of nitric oxide (NO); and potentiation of adrenergic
and other vasoconstrictor agents. A short discussion of vascular smooth muscle contraction pathways is necessary to understand the interaction of vasopressin.

All muscle cells use calcium as a signal for contraction. Vascular smooth muscle cells are regulated by a variety of neurotransmitters and hormones; these interact with a network of signal transduction pathways that ultimately affect contractility either by affecting calcium levels in the cell or the response of the contractile apparatus to calcium. Calcium levels are increased by extracellular entry via voltage-gated calcium channels and by release from intracellular stores. At high cytosolic concentrations, calcium forms a complex with calmodulin that activates a kinase, which phosphorylates the regulatory light chain of myosin. Phosphorylated myosin activates myosin ATPase by actin and the cycling of myosin cross-bridges along actin filaments, which contracts the muscles. Vasodilation occurs when a kinase interacts with myosin phosphatase, which dephosphorylates myosin and prevents muscle contraction [14].

Vasopressin, norepinephrine, and angiotensin II act on cell surface receptors that couple with G-proteins to effect vasoconstriction. Vasopressin interacts with V1R, which are found in high density on vascular smooth muscle, through the G_{q,11} pathway to stimulate phospholipase C and produce the intracellular messengers inositol trisphosphate (IP3) and diacylglycerol. These second messengers then activate protein kinase C and elevate intracellular free calcium to initiate contraction of vascular smooth muscle. In contrast, vasodilators such as atrial natriuretic peptide (ANP) and NO activate a cGMP-dependent kinase that, by interacting with myosin phosphatase, dephosphorylates myosin and thus prevents muscle contraction [14]. The opposing influences of these pathways are important in determining the functional state of vascular smooth muscle, and integration of this signaling is a key component in vascular homeostasis [15].

A key mechanism by which vascular smooth muscle tone is controlled is through K+ channels [16]. The resting membrane potential of vascular smooth muscle ranges from –30 mV to –60 mV. A more positive potential (depolarization) opens voltage-gated calcium channels, increasing cytosolic Ca^{2+} concentration, and induces vasoconstriction. Conversely, hyperpolarization closes these channels, decreases cytosolic Ca^{2+} concentration, and induces vasodilation [13]. The membrane potential of vascular smooth muscle is controlled by a number of ion transporters and channels, particularly K+ channels. The opening of K+ channels allows an efflux of potassium, thus hyperpolarizing the plasma membrane and preventing entry of calcium into the cell [16], even in the presence of vasoconstrictor agents [17].

Four types of K+ channels have been described (Table 1) [16]. Of these, the K_{ATP} channel is the best understood and plays a critical role in disease states such as vasodilatory shock. K_{ATP} channels are physiologically activated by decreases in cellular ATP and by increases in the cellular concentrations of hydrogen ion and lactate [18,19]. This activation prevents opening of voltage-gated Ca^{2+} channels and contributes to the vasoplergia (resistance to catecholamines) that is seen in shock states.

Activation of K_{ATP} channels is a critical mechanism in the hypotension and vasodilation that are characteristic of vasodilatory shock. Agents that close K_{ATP} channels (such as sulfonylureas) have been shown to increase arterial pressure and vascular resistance in vasodilatory shock due to hypoxia [20], in septic shock [20–22], and in the late, vasodilatory phase of hemorrhagic shock [23]. An important mechanism by which vasopressin restores vascular tone in vasoplegic (catecholamine-resistant) shock states may be its ability to close K_{ATP} channels [24].

Another mechanism by which vasopressin exerts vascular control is through modulation of NO. The latter contributes to the hypotension and resistance to vasopressor drugs that occur in vasodilatory shock. The vasodilating effect of NO is mediated mainly by the activation of myosin light-chain phosphatase. However, NO also activates K+ channels in the vascular smooth muscle [25,26]. Agents that block NO synthesis during septic shock increase arterial pressure and decrease the doses of vasoconstrictor catecholamines needed to maintain arterial pressure [27]. Vasopressin may restore vascular tone in vasodilatory shock states by blunting the increase in cGMP that is induced by NO [28] and ANP [29], and by decreasing the synthesis of inducible nitric oxide synthase (NOS) that is stimulated by lipopolysaccharide [28]. This inhibition occurs via the V_{1A} receptor [30,31].

Vasopressin potentiates the vasoconstrictor effects of many agents, including norepinephrine [32,33] and angiotensin II [34–36]. The underlying mechanism of this is unknown but possibilities include coupling between G-protein-coupled receptors [36], interaction between G-proteins, and interference with G-protein-coupled receptor downregulation through arrestin trafficking.

Vasopressin has been demonstrated to cause vasodilation in numerous vascular beds [37–44] – a feature not shared by other vasoconstrictor agents. The mechanism of vasodilation has been demonstrated to be due to activation of endothelial otecin receptors (OTRs) [45], which in turn trigger activation of endothelial isoforms of NOS.

Whether vasopressin causes vasoconstriction or vasodilation depends on the vascular bed studied [46], which may, in turn, depend on the receptor density (V_{1A} versus OTR), the model studied, the dose of vasopressin [47], and the duration of exposure to the hormone [48]. Indeed, the opposing influences of various pathways that determine the functional state of vascular smooth muscle is an area for further study. For
example, prolonged exposure to cAMP inhibits both angiotensin II and vasopressin-stimulated phosphoinositide hydrolysis and intracellular calcium mobilization [49]. Adenylyl cyclases present a focal point for signal integration in vascular smooth muscle, and type III adenylyl cyclase has been proposed as a key subtype for cross-talk between constrictor and dilator pathways [50]. The important question is whether vasopressin can cause simultaneous vasoconstriction of some vascular beds and vasodilation of others.

Vasopressin and the heart

The actions of vasopressin on the heart are complex and the studies are seemingly contradictory. Depending on the species studied, the dose used, and the experimental model, vasopressin can cause coronary vasoconstriction or vasodilation and exert positive or negative inotropic effects. In addition to its vascular effects on coronary blood flow, vasopressin also has mitogenic and metabolic effects on the heart.

Coronary vascular tone

The effect of vasopressin on the coronary vascular bed is controversial. Several investigators have demonstrated a V_1R-mediated coronary vasoconstrictor response to vasopressin [51–54] – an effect that appears to be dose dependent [55,56] and intensified by removal of endothelium [46]. In contrast, coronary vasodilation in response to vasopressin has been demonstrated in isolated canine [57,58] and primate [44] coronary arteries. More recently, vasopressin was demonstrated to cause coronary vasodilation in an intact animal model. A bolus injection of vasopressin significantly increased the vascular diameter of the left anterior descending artery in pigs [59]. This vasodilation was present during sinus rhythm, ventricular fibrillation, and after successful cardiopulmonary resuscitation. Vasopressin probably effects coronary vasodilation through control of endothelial tone [58], as has been demonstrated in the pulmonary vasculature [39].
A difference between the ‘normal’ and stressed heart in their responses to vasopressin has been reported, with vasoconstriction seen in normoxic state and vasodilation seen during hypoxia [60]. Using an isolated working rat heart model, high-dose vasopressin (777 ± 67 pg/ml) reduced coronary flow by 38.4 ± 2.6% in normoxic hearts. Myocardial function was also significantly decreased by vasopressin. In contrast, the same dose of vasopressin administered to hypoxic hearts resulted in a smaller decrease in coronary blood flow (−11.5 ± 2.8%) and an improvement in myocardial function. Interestingly, in hearts treated first with vasopressin and then with hypoxia, there was a greater degree of coronary vasodilation as compared with that observed in hearts treated with hypoxia alone. These results indicate that the vasoconstrictor effect of vasopressin on the coronary vessels, as well as its effect on the myocardium, may be dependent on oxygen tension and possibly on the redox state of the cell. In addition, vasopressin-constricted vessels appear to retain considerable vasodilatory reserve, despite evidence of ischemic conditions [60].

Several preclinical studies have evaluated vasopressin in animal models of cardiac arrest [61–64]. These studies suggested that vasopressin leads to superior resuscitation rates as compared with epinephrine (adrenaline). The improvement in restoration of spontaneous circulation is partially ascribed to an improvement in coronary blood flow [65]. However, in the setting of cardiac arrest, the improvement in coronary blood flow is probably mediated by an improvement in coronary perfusion pressure as opposed to vasopressin-mediated coronary vasodilation.

**Inotropy**

Studies of the inotropic effects of vasopressin are also controversial, and the effects appear to depend on the dose used and the model studied. In a study of an isolated working rat heart model, investigators found that high-dose vasopressin (878 pg/ml) produced significant decreases in coronary flow, myocardial oxygen consumption and left ventricular peak systolic pressure, and a small decrease in cardiac output [55]. Similarly, intracoronary infusion of vasopressin-dextran (a method employed to keep the vasopressin in the vascular compartment) in isolated perfused guinea pig hearts caused coronary vasoconstriction and negative inotropy – effects that were blocked with vasopressin antagonists and P2 purinergic receptor antagonist [66]. These results were duplicated in conscious dogs, in which an infusion of low-dose vasopressin (15 pg/ml) caused significant increases in left ventricular end-systolic pressure, end-systolic volume, total systemic resistance, and arterial elastance, whereas the heart rate and stroke volume were decreased. There was no significant change in coronary sinus blood flow. Vasopressin decreased the slope of the left ventricular end-systolic pressure–volume relation, the maximal first derivative of left ventricular pressure/end-diastolic volume relation, and the stroke work–ventricular end-diastolic relation, and shifted the relations to the right, indicating a depression of left ventricular performance [67]. The relevance of these observations in the setting of vasodilatory shock in humans, however, is not known.

It is often difficult to isolate the effects of vasopressin on inotropy from its effects on coronary blood flow. Indeed, when attempts were made to study the effects of vasopressin on the heart independently of coronary blood flow, the effects of vasopressin on inotropy were strikingly different. By maintaining constant coronary flow, the direct cardiac effects of vasopressin on an isolated rat heart preparation were determined, independent of changes in myocardial oxygen delivery elicited by coronary vasoconstriction [56]. Myocardial function was assessed at vasopressin concentrations of 0, 10, 25, 50, 100, 200, 400, and 500 pg/ml. Progressive coronary vasoconstriction was observed with increasing vasopressin concentration. In contrast, peak ventricular pressure and the first derivative of left ventricular pressure (dP/dt\text{max}) increased at 50 and 100 pg/ml vasopressin but fell at 400 and 500 pg/ml. The maximal peak ventricular pressure and dP/dt\text{max} responses were at 50 pg/ml, whereas at 500 pg/ml both peak ventricular pressure and dP/dt\text{max} were reduced below control. Pretreatment with a specific V1R antagonist totally blocked both the coronary vasoconstrictor and contractility responses to vasopressin. These data suggest that, although vasopressin causes dose-related coronary vasoconstriction and negative inotropy at high vasopressin concentrations, the hormone may exert a net positive inotropic effect at low doses. It appears that the net effect of vasopressin on cardiac function in an intact preparation will depend on the concentration of vasopressin as well as on the relative balance of its effects on coronary perfusion pressure (diastolic blood pressure), coronary vascular tone, and any direct effects on the inotropic state of the myocardium.

The clinical observation that vasopressin greatly increases afterload in vasodilatory shock (systemic vascular resistance [SVR] nearly doubles) but depresses cardiac output relatively little (14%) led to speculation that vasopressin at low doses might have positive inotropic effects [3]. Furthermore, in a small trial of vasopressin in patients with heart failure and vasodilatory hypotension due to the phosphodiesterase inhibitor milrinone, vasopressin increased SVR but did not depress cardiac output [68], again suggesting a positive inotropic action. However, these conclusions are speculative because it is difficult to isolate the effects of vasopressin on contractility from its effects on coronary perfusion, heart rate, and ventricular preload. Of more importance is the net clinical benefit of these often contradictory actions. An observational study conducted in critically ill humans specifically examined the effects of low-dose vasopressin infusion on hemodynamics and cardiac performance [69]. In 41 patients with catecholamine-resistant postcardiotomy shock, continuous infusion of vasopressin was associated with a significant increase in left ventricular stroke work index and a significant decrease in heart rate, as well as vasopressor and inotropic requirements. Cardiac index and stroke volume remained
unchanged despite a significant reduction in the requirement for inotropic agents. Interestingly, myocardial enzymes significantly fell in all patients and many patients with atrial arrhythmias converted on infusion. The authors concluded that low-dose vasopressin improved myocardial performance in this group of patients.

Classically, the effects of vasopressin on the heart were thought to be mediated through the V₁R (vascular smooth muscle/calcium-dependent effect) or OTR (endothelial/NO effect). Neonatal rat cardiomyocytes possess V₁Rs [70], and vasopressin causes a dose-dependent increase in intracellular calcium, which is dependent on extracellular magnesium and calcium concentrations, secondary to V₁R activation and phospholipase-mediated IP₃ generation [71]. The V₁R also mediates prostacyclin and ANP release from cultured rat cardiomyocytes exposed to vasopressin [72]. OTRs were also identified in isolated rat heart, and oxytocin causes increased ANP release in perfused rat heart preparations [73]. The negative inotropic and chronotropic effects of oxytocin may be mediated by these cardiac OTRs. Blockade of cholinergic receptors and NO production attenuated the negative effects of oxytocin on cardiac function [74]. More recently it was suggested that the cardiac effects of vasopressin are due to selective activation of intravascular purinoceptors and that an intermediary of these effects is ATP [66]. Indeed, adenoviral gene transfer of the V₂ renal receptor (V₂R) into cardiomyocytes was shown to modulate the endogenous cAMP signal cascade and increase contractility of rat cardiomyocytes [75].

In the setting of primary cardiac dysfunction, however, it is the effect of vasopressin on SVR that may counter any potential beneficial effects on cardiac inotropy. Indeed, antagonism of vasopressin receptors has been advocated as therapy for congestive heart failure; both animal models of congestive heart failure and early clinical studies support the notion that antagonism of V₁Rs and V₂Rs leads to an improvement in cardiac function, probably mediated through reductions in cardiac afterload [76–78].

**Cardiac hypertrophy**

Vasopressin promotes cardiac hypertrophy in neonatal rat hearts via direct effects on cardiomyocyte protein synthesis secondary to IP₃-mediated intracellular calcium release [79]. In the adult rat heart, vasopressin directly increased the rate of protein synthesis via the V₁R, which was sensitive to amiloride – a mechanism that differs from the cAMP-dependent mechanism that is responsible for the cardiac hypertrophy induced by pressure overload [80].

**Summary**

V₁R-mediated coronary vasoconstriction is a dose-dependent phenomenon that is attenuated by the endothelial vasodilating properties of vasopressin action via the OTR or P₂ purinergic receptor. When cardiac contractility is studied independently of coronary perfusion, vasopressin may have a positive inotropic effect at low doses. Further work is necessary to determine the significance of these observations in human hearts in both health and disease states.

**Clinical application of vasopressin in shock**

In health, vasopressin’s role in the maintenance of resting arteriolar tone and systemic blood pressure is minor. Indeed, high concentrations of vasopressin are required before vasoconstrictor effects are seen. It is only during shock states that vasopressin’s role in the maintenance of systemic blood pressure is seen. Indeed, vasopressin deficiency and hypersensitivity to the hormone’s pressor effects appear to be a hallmark of vasodilatory shock states [13]. These states include vasodilatory septic shock [1–5], vasodilatory shock post-cardiopulmonary bypass [6–9, 81], vasodilatory shock due to phosphodiesterase inhibition in the treatment of heart failure [12, 86], hemodynamically unstable organ donors [11], and the late, so-called ‘irreversible’ phase of volume treated hemorrhagic shock [82]. The reason for the reduction in circulating concentration of vasopressin has not been fully determined. However, depletion of neurohypophyseal stores has been observed in profound shock states [83].

The use of vasopressin clinically has followed observations that endogenous administration of vasopressin during shock is capable of restoring systemic blood pressure. Landry and coworkers [4] first demonstrated this property in five patients with advanced septic shock. Since their initial observations, several uncontrolled trials have demonstrated that vasopressin can restore blood pressure during septic shock, following cardiopulmonary bypass and following epinephrine-resistant cardiac arrest (Table 2). However, few controlled studies have been performed to evaluate properly the effectiveness of vasopressin in shock. This is a critical point because it cannot be inferred that if an agent restores blood pressure then it will also lead to an improvement in outcome. An increase in blood pressure may be being obtained at the expense of perfusion to critical organs, or it may worsen cardiac performance by impairment of ventricular output through an increase in ventricular afterload. Consequently, organ injury could worsen in the face of a restoration of blood pressure. A case in point is the manner in which NOS inhibition was embraced to treat shock in septic patients [84]. Indeed, NOS inhibitors have clinical effects that are similar to those of vasopressin. Several reports have documented an increase in blood pressure, reduction in pressor requirement, and attendant reduction in cardiac output [84–86] (a profile that resembles that of vasopressin) in patients with septic shock. However, a recent randomized controlled trial of a NOS inhibitor in septic shock was halted because of higher mortality rates in the group that received treatment [87].

At present the only blinded, systematic evaluation of vasopressin in sepsis is that recently reported by Patel and coworkers [2]. In a controlled manner, they compared the effects of vasopressin with those of norepinephrine in
24 patients with septic shock who required vasopressor infusions. Patients who received vasopressin had a significant (80%) reduction in vasopressor requirement. Interestingly, patients in the vasopressin arm experienced a doubling in urine output and a 75% increase in creatinine clearance. Based on current information, it appears that replacement of vasopressor at a fixed dose can eliminate the need for catecholamine pressors in many patients.

Vasopressin was also evaluated in the setting of hypotension following induction of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors [88,89]. One study compared terlipressin (a vasopressin agonist) plus ephedrine (n=21) versus ephedrine alone (n=19) in patients following induction of anesthesia [88]. The second study evaluated vasopressin (n=13) compared with placebo (n=14) in patients following cardiac bypass [89]. Both studies demonstrated that the vasopressin agonist led to better hemodynamic stability and less catecholamine use. Consequently, in patients who are refractory to conventional vasopressors (owing to chronic blockade of their renin–angiotensin system), vasopressin may offer some clinical benefit in improving hemodynamics. Indeed, the study conducted by Morales and coworkers [89] demonstrated that, among those patients chronically treated with angiotensin-converting enzyme inhibitors, the group that received vasopressin had a shorter duration of stay in the intensive care unit following induction of anesthesia. These studies must be repeated in order to evaluate these highly relevant end-points and to confirm the safety of vasopressin before widespread clinical use of this agent can be recommended.

Vasopressin has also been demonstrated to increase arterial and coronary perfusion pressure as compared with clinical doses of epinephrine in animal models of cardiac arrest. Interestingly, like epinephrine, vasopressin may also be administered via the endotracheal tube. In fact, vasopressin had better hemodynamic effects than did intratracheal epinephrine in one study of a canine model of cardiac arrest [90]. Based on these favorable reports, vasopressin has been advocated for use in cardiac arrest. In 1997, Lindner and coworkers [91] reported the effects of 40 units of vasopressin versus 1 mg epinephrine in patients who had not responded to three counter-shocks in the field. Fourteen (70%) patients in the vasopressin group versus seven (35%) patients in the epinephrine group survived to hospitalization. However, in a more recent study of vasopressin in cardiac arrest, no benefit over epinephrine was found [92]. That study evaluated vaso-

### Table 2

**Clinical trials of low-dose vasopressin in vasodilatory shock states**

| Reference | Year | Trial Type | n  | Patients | Findings |
|-----------|------|------------|----|----------|----------|
| [4]       | 1997 | Case series| 5  | Septic shock | A, B, C  |
| [3]       | 1997 | Matched cohort | 19 | Septic shock | A, B, D in septic group |
|           |      |            | 12 | Cardiogenic shock |     |
| [5]       | 1999 | RCT        | 10 | Septic shock – trauma | A, B |
| [2]       | 2000 | RCT        | 24 | Septic shock | A, B, C, D |
| [94]      | 2001 | Retrospective | 60 | Septic and postcardiomyotony shock | A, B, ↓CI |
| [95]      | 2001 | Prospective, case-controlled | 16 | Septic shock | A, B, C |
| [7]       | 1998 | Retrospective case series | 40 | Postbypass vasodilatory shock | A, B, D |
| [6]       | 1997 | RCT        | 10 | Vasodilatory shock post-LVAD implant | A, B in treatment arm; D in all |
|           |      | Placebo: N/S |      |            |          |
| [8]       | 1999 | Case series | 20 | Vasodilatory shock post-cardiac transplant | A, B |
| [9]       | 1999 | Case series | 11 | Pediatric – vasodilatory shock postbypass | A, B, D |
| [10]      | 2000 | Retrospective case series | 50 | Vasodilatory shock post-LVAD implant | A, B |
| [69]      | 2002 | Retrospective | 41 | Postcardiomyotony shock | A, B |
| [11]      | 1999 | Case series | 10 | Organ donors with vasodilatory shock | A, D |
| [68]      | 2000 | Case series | 7  | Milrinone – hypotension | A, B, C |

Findings are classified as follows: A, increase in blood pressure; B, decrease or discontinuance of catecholamines; C, increase in urine output; and D, low plasma vasopressin levels in subjects. CI, cardiac index; LVAD, left ventricular assist device; N/S, normal saline; RCT, randomized controlled trial.
Vasopressin versus epinephrine as the first agent given in 200 patients who suffered in-hospital cardiac arrest. The investigators found that there was no advantage with either agent with respect to 1-hour survival or survival to hospital discharge. Importantly, there was no difference between groups in Mini Mental Status Examination or cerebral performance category scores. The reason for the discrepancy between the two studies is unclear. One explanation is differences between the two populations evaluated. Lindner and coworkers [91] evaluated patients who suffered a cardiac arrest out of hospital, whereas Steill and coworkers [92] evaluated hospitalized patients. Hospitalized patients may have a different prognosis after cardiac arrest than that of their counterparts in the community. Similarly, the etiology of the cardiac arrest may also have differed between the two groups, with more patients having a primary cardiac event in the community.

Administration of vasopressin to patients in low flow states (i.e. cardiogenic or hypovolemic shock) is strongly contraindicated because in these states cardiac output is severely depressed by the increase in afterload. Indeed, blockade of V1Rs and V2Rs has been advocated for treating congestive heart failure. In a rat model of congestive heart failure a single oral administration of conivaptan (a V1R and V2R blocker) increased urine concentration of vasopressin V1Rs and plays a major role in retaining free water and plays a significant role in elevating vascular tone through vasoconstrictor properties, clinical studies of low-dose vasopressin to date do not demonstrate adverse cardiac effects of vasopressin. In refractory shock states, administration of vasopressin in low, physiologic doses has been associated with impressive stabilization of hemodynamics. Vasopressin is gaining popularity in diverse states such as septic shock and vasodilatory states associated with cardiac anesthesia and surgery. We stress that the clinical studies to date have been small and have focused on physiologic outcomes, and data on adverse effects are limited. Therefore, we do not recommend vasopressin as first-line therapy for vasodilatory shock. Future prospective studies are necessary to define the role of vasopressin in the therapy of vasodilatory shock.

**Competing interests** None declared.

**References**

1. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA: The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. *Intensive Care Med* 2001, 27:1416-1421.
2. Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology* 2002, 96:576-582.
3. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Sos S, D’Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasopressin of septic shock. *Circulation* 1997, 95:1122-1125.
4. Landry DW, Levin HR, Gallant EM, Sos S, D’Alessandro D, Oz MC, Oliver JA: Vasopressin pressor hypersensitivity in vasodilatory septic shock. *Crit Care Med* 1997, 25:1279-1282.
5. Malay MB, Ashton RC Jr, Landry DW, Townsend RN: Low-dose vasopressin in the treatment of vasodilatory septic shock. *J Trauma* 1999, 47:699-703; discussion 703-705.
6. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. *Circulation* 1997, 96:II-286-II-290.
7. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfink E, Weinberg AD, Smith CR Jr, Rose EA, Landry DW, Oz MC: Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. *J Thorac Cardiovasc Surg* 1998, 116:973-980.
8. Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR, Edwards NM, Landry DW, Oz MC: Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. *J Heart Lung Transplant* 1999, 18:814-817.
9. Rosenzweig EB, Stark TJ, Chen JM, Cullinane S, Timchak DM, Gersony WM, Landry DW, Galantowicz ME: Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. *Circulation* 1999, 100:1812-1816.
10. Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, Oz MC: Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. *Ann Thorac Surg* 2000, 69:102-106.
11. Chen JM, Cullinane S, Spanier TB, Antip RH, John R, Edwards NM, Oz MC, Landry DW: Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. *Circulation* 1999, 100:II-244-II-246.
12. Gold JA, Cullinane S, Chen J, Oz MC, Oliver JA, Landry DW: Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. *Crit Care Med* 2000, 28:249-252.
13. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. *N Engl J Med* 2001, 345:588-595.
14. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME: Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Ialpha. *Science* 1999, 286:1583-1587.
15. Webb JG, Yates PW, Yang Q, Mukhin YV, Lanier SM: Adenylyl cyclase isoforms and signal integration in models of vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol* 2001, 281:H1545-H1552.
Critical Care  February 2004 Vol 8 No 1 Holmes et al.

16. Standen NB, Quayle JM: K⁺ channel modulation in arterial smooth muscle. Acta Physiol Scand 1998, 164:549-557.
17. Jackson WF: Ion channels and vascular tone. Hypertension 2000, 35:173-178.
18. Davies NW: Modulation of ATP-sensitive K⁺ channels in skeletal muscle by intracellular protons. Nature 1990, 343:375-377.
19. Keung EC, Li Q: Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest 1991, 88:1727-1737.
20. Landry DW, Oliver JA: The ATP-sensitive K⁺ channel mediates hypotension in endotoxemia and hypoxic lactacidosis in dog. J Clin Invest 1992, 89:2071-2074.
21. Geisen K, Vehg A, Krause E, Papp JG: Cardiovascular effects of cyanine dyes and gliiperimide. Horm Metab Res 1996, 28:496-507.
22. Gardiner SM, Kemp PA, March JE, Bennett T: Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide. Br J Pharmacol 1999, 127:1789-1797.
23. Salzman AL, Vromen A, Denenberg A, Szabo C: K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 1997, 272:H688-H694.
24. Wakatsuki T, Nakaya Y, Houe I: Vasopressin modulates K⁺(ATP) channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 1992, 263:H491-H496.
25. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994, 368:850-853.
26. Archer SL, Hwang J, Hampi V, Nelson DP, Shultz PJ, Weir EK: Nitric oxide and cGMP cause vasorelaxation by activation of a charybdoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994, 91:7583-7587.
27. Kilbourn R: Nitric oxide synthase—a mechanism-based enzyme. Drug News Perspect 1996, 9:373-377.
28. Umino T, Kusano E, Umeda M, Asahina M, Omae Y, Hori S, Shindo Y, Endo M: Arginine vasopressin inhibits AVP-sensitive K⁺ channel activity in cultured rat mesangial cells. Kidney Int 1996, 49:722-729.
29. Wang HL, Voelkel NF: Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol 1989, 257:H415-H422.
30. Erough PR, Pearson PJ, Schaff HV: Arginine vasopressin induces endothelium-dependent vasodilation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1998, 103:1241-1245.
31. Suzuki Y, Satoh S, Oyama H, Takayasu M, Shibuya M: Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke 1993, 24:1049-1053; discussion 1053-1044.
32. Rudichenska VM, Benwarelt WH: Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res 1995, 32:100-105.
33. Takami T, Kiyomoto K, He H, Tomohiro A, Nishiyama A, Aki Y, Kimura S, Abe Y: Vasodilation induced by vasopressin V2 receptor stimulation in arterial and mesenteric resistance vessels. Circ Res 1996, 38:7583-7587.
34. Okamura T, Toda M, Ayaike K, Toda N: Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J Vasc Res 1997, 34:464-472.
35. Geisen K, Vehg A, Krause E, Papp JG: Cardiovascular effects of cyanine dyes and gliiperimide. Horm Metab Res 1996, 28:496-507.
36. Gardiner SM, Kemp PA, March JE, Bennett T: Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide. Br J Pharmacol 1999, 127:1789-1797.
37. Salzman AL, Vromen A, Denenberg A, Szabo C: K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 1997, 272:H688-H694.
38. Wakatsuki T, Nakaya Y, Houe I: Vasopressin modulates K⁺(ATP) channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 1992, 263:H491-H496.
39. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994, 368:850-853.
40. Archer SL, Hwang J, Hampi V, Nelson DP, Shultz PJ, Weir EK: Nitric oxide and cGMP cause vasorelaxation by activation of a charybdoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994, 91:7583-7587.
41. Kilbourn R: Nitric oxide synthase—a mechanism-based enzyme. Drug News Perspect 1996, 9:373-377.
42. Umino T, Kusano E, Umeda M, Asahina M, Omae Y, Hori S, Shindo Y, Endo M: Arginine vasopressin inhibits AVP-sensitive K⁺ channel activity in cultured rat mesangial cells. Kidney Int 1996, 49:722-729.
Boyle WA III, Segel LD: Attenuation of vasopressin-mediated coronary constriction and myocardial depression in the hypoxic heart. Circ Res 1990, 68:710-721.

Wenzel V, Lindner KH, Bahlmann MA, Voelckel WG: Vasopressin decreases endogenous catecholamine plasma concentrations during cardiopulmonary resuscitation in pigs. Crit Care Med 2000, 28:1096-1100.

Raedler C, Voelckel WG, Wenzel V, Bahlmann L, Baumeier W, Schoneberg T, Herth H, KR, Lurie KG: Vasopressor response in a porcine model of hypothermic cardiac arrest is improved with active compression-decompression cardiopulmonary resuscitation using the inspiratory impedance threshold valve. Anesth Analg 2002, 95:1496-1497.

Voelckel WG, Lurie KG, McKnite S, Zielinski T, Lindstrom P, Peterson C, Wenzel V, Lindner KH, Benditt D: Effects of epinephrine and vasopressin in a piglet model of prolonged ventricular fibrillation and cardiopulmonary resuscitation. Crit Care Med 2002, 30:497-500.

Wenzel V, Lindner KH, Kramer AC, Miller EA, Voelckel WG, Lingnau W: Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation. Circulation 1999, 99:1379-1384.

Zenteno-Savin T, Sada-Ovalle I, Ceballos G, Rubio R: Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. Eur J Pharmacol 2000, 410:19-23.

Cheng CP, Igarashi Y, Kloppefenstein HS, Applegate RJ, Shihabi Z, Little WC: Effect of vasopressin on left ventricular performance. Am J Physiol 1993, 264:H53-H60.

Gold J, Cullinane S, Chen J, Seo S, Oz MC, Oliver JA, Landry DW: Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol 2000, 85:508-506, A511.

Dunser MW, Mayr AJ, Stallinga A, Ulmer H, Ritsch N, Knotzer H, Pajk W, Mutz NJ, Hasibeder WR: Cardiac performance during vasopressin administration in postcardiotomy shock. Intensive Care Med 2002, 28:746-751.

Yu XJ, Gopalakrishnan V: Vasopressin increases cytosolic free [Ca2+]i in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res 1991, 69:239-245.

Liu P, Hoppel CD, Xu YJ, Gopalakrishnan V: Vasopressin-evoked [Ca2+]i responses in neonatal rat cardiomyocytes. J Cardiovasc Pharmacol 1999, 34:540-546.

Van der Bent V, Church DJ, Vallotton MB, Medel P, Kem DC, Capponi AM, Lang U: [Ca2+]i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. Am J Physiol 1994, 266:H967-H965.

Gutkowska J, Janowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM: [Ca2+]i and protein kinase C in vasoressin-induced hypotension. V1a and V2 receptor antagonist, in patients with out-of-hospital ventricular fibrillation. Circ Res 1999, 85:925-933.

Lindner KH, Dirks B, Strotheminger HU, Prengel AW, Lindner IM, Lurie KG: Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997, 349:533-537.

Stiell IG, Hebert PC, Wells GA, Vanderheen KL, Tang AS, Higginson LA, Dreyer F, Clement C, Battrem E, Watpool I, Mason S, Klassen T, Weitzen BN: Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 1999, 354:105-109.

Cooper DJ, Russell JA, Walley KR, Holmes CL, Singer J, Hebert PC, Granton J, Mehta S, Teniers T: Vasopressin and septic shock trial (VASSIT): innovative features and performance. Am J Respir Crit Care Med 2003, 167:A838.

Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Mutz NJ, Hasibeder WR: The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2003, 96:37-43.

Available online http://ccforum.com/content/8/1/15